British Columbia

B.C.'s 10-Year Cancer Action Plan (2023–2033) carries an initial CAD $440 million investment announced in 2023 and is delivered through six regional cancer centres, with reported year-one hiring of over 70 oncologists and more than 30 radiation therapists; no pancreatic-specific provisions are documented.

The Cancer Genetics & Genomics Laboratory holds a provincial mandate for molecular diagnostics for all cancer patients in BC, recorded "In effect" — an operational province-wide program, though the corpus does not describe a standardized funding-and-coordination program of the Ontario type.

BC is one of three CRAFT pilot provinces for decentralized trials and is listed among the provinces with clinical trial sites. Not obtainable: no BC enrolment rate and no BC pancreatic-specific trial program is documented in the corpus.

The only BC patient-cost support documented is charitable: the BC Cancer Foundation's donor-funded Patient Relief Fund (established ~2019, ongoing); the corpus documents no BC provincial travel program and contrasts the fund with the absence of a dedicated province-wide relief fund in Atlantic Canada.

BC operates a province-wide integrated outcomes platform (OaSIS/COSI), and its action plan's first year filled over 325 FTE positions including oncologists and radiation therapists and established eight Indigenous patient navigator positions; no retention mechanisms are documented.

The University of British Columbia holds the largest institutional share of the national CIHR register (46 of 270 records), and BC hosts a major pancreatic-flagged grant in the filtered register (Simon Fraser University, $994,500). (The representation inventories measure Atlantic representation only; this score rests on hosted funding and infrastructure.)